Antiandrogens in the Treatment of Prostate Cancer

Abstract Objectives To give an overview on the contemporary role of antiandrogens in prostate cancer treatment. Methods A review of the literature was performed concerning pharmacologic properties, possible indications and side effects of antiandrogens in the treatment of early and advanced prostate...

Full description

Saved in:
Bibliographic Details
Published in:European urology 2007-02, Vol.51 (2), p.306-314
Main Authors: Wirth, Manfred P, Hakenberg, Oliver W, Froehner, Michael
Format: Article
Language:English
Subjects:
Androgen Antagonists - adverse effects
Androgen Antagonists - therapeutic use
Antiandrogens
Bicalutamide
Biological and medical sciences
Combined Modality Therapy
Cyproterone acetate
Flutamide
Gynecology. Andrology. Obstetrics
Hormonal treatment
Humans
Male
Male genital diseases
Medical sciences
Nephrology. Urinary tract diseases
Nilutamide
Prostate cancer
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - therapy
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objectives To give an overview on the contemporary role of antiandrogens in prostate cancer treatment. Methods A review of the literature was performed concerning pharmacologic properties, possible indications and side effects of antiandrogens in the treatment of early and advanced prostate cancer. Results One steroidal and three non-steroidal antiandrogens are in common use for the treatment of prostate cancer. Monotherapy with non-steroidal antiandrogens may prevent osteoporosis, loss of musculature and may preserve sexual activity in a proportion of patients and therefore has advantages in quality of life compared to castration. In patients with localized disease managed by watchful waiting or in an adjuvant setting, there are no studies showing an advantage in early versus delayed treatment with antiandrogens regarding clinical progression. In locally advanced non-metastatic prostate cancer, antiandrogen monotherapy seems to be an alternative to castration treatment if treatment is required. In patients with metastatic disease and a high tumor burden, antiandrogen monotherapy is inferior to castration. In advanced disease, combined androgen blockade can provide a small survival advantage, which, however, has to be balanced against increased side effects and costs. Conclusions Antiandrogens are a treatment option in some patients with prostate cancer. However, it has to be taken into account that the hormonal effect is inferior to castration.
ISSN:0302-2838
1873-7560
DOI:10.1016/j.eururo.2006.08.043